Drug intelligence / Profile preview

miR-148a-3p mimics

Development stage
Preclinical
Lead developer
National Central University
Modality
RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intratumoral, Intraperitoneal
01

Overview

miR-148a-3p mimics are synthetic RNA molecules designed to replicate the activity of the endogenous microRNA miR-148a-3p. In oncology research, specifically for head and neck cancer, these mimics function as radiosensitizers by directly targeting and suppressing the expression of Integrin alpha-5 (ITGA5). By inhibiting the ITGA5 signaling pathway, miR-148a-3p mimics reduce cancer cell proliferation and migration, promote DNA damage and genomic instability, and induce G2/M phase arrest following radiation exposure. Additionally, they have been shown to mitigate radiation-induced bystander effects (RIBEs), which are responsible for secondary tumorigenesis and metastasis. Recent developments involve the use of Wharton's Jelly Mesenchymal Stem Cell (WJMSC)-derived exosomes as a delivery vehicle to transport these mimics into target cancer cells, enhancing their therapeutic potential during radiotherapy.

Other names
microRNA-148a-3p mimicsmicroRNA148a-3p mimicsmicroRNA 148a-3p mimicsmiR-148a-3pmiR148a-3pmiR 148a-3p
02

Targets

Integrin subunit alpha 5 mRNAPRNP (Cellular Prion Protein)SMAD2 (Mothers against decapentaplegic homolog 2)ITGA5 (Integrin alpha-5)TGFBR1

Beyond the preview

Go deeper on miR-148a-3p mimics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-148a-3p mimics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call